Faricimab approval, home OCT mark major developments in retina

WASHINGTON — Recent developments in the retina field include increasingly durable therapeutics for vascular disease, according to a speaker here.
“It’s an exciting time in the world of retina,” Brian K. Do, MD, said at the American Society of Cataract and Refractive Surgery meeting.
Do discussed updates in the specialty, such as the approval of faricimab for neovascular age-related macular degeneration and diabetic macular edema. Because faricimab is a bispecific monoclonal antibody, it is able to inhibit both VEGF-A and Ang-2.
“Ang-2 is thought, when inhibited, to

WASHINGTON — Recent developments in the retina field include increasingly durable therapeutics for vascular disease, according to a speaker here.
“It’s an exciting time in the world of retina,” Brian K. Do, MD, said at the American Society of Cataract and Refractive Surgery meeting.
Do discussed updates in the specialty, such as the approval of faricimab for neovascular age-related macular degeneration and diabetic macular edema. Because faricimab is a bispecific monoclonal antibody, it is able to inhibit both VEGF-A and Ang-2.
“Ang-2 is thought, when inhibited, to